search
Back to results

Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy

Primary Purpose

Brain Neoplasms

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
dexmedetomidine
normal saline
Sponsored by
Peking University First Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Brain Neoplasms focused on measuring child, craniotomy, intelligence tests, dexmedetomidine, Disruption, Dehiscence, Mild Cognitive Disorder

Eligibility Criteria

2 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age of 2 years or older, but no more than 12 years;
  2. Plan to undergo selective craniotomy under general anesthesia for intracranial tumor resection;
  3. Written informed consent signed by legal guardians.

Exclusion Criteria:

  1. Refused to participate by the legal guardians;
  2. Body weight lower than the 3rd percentile or higher than 97th percentile of the normal body weight reference;
  3. American Society of Anesthesiologists physical classification of IV or higher;
  4. Unable to complete preoperative intelligence assessment because of coma, dysnoesia, or language barrier;
  5. Diagnosed pulmonary disease (including acute respiratory tract infection) or cardiovascular disease (including congenital heart disease, hypertension, hypotension, bradycardia, atrioventricular block, or cardiac insufficiency);
  6. Abnormal liver or renal function (liver enzyme or creatinine higher than 1.5 times of the upper normal limit;
  7. Other congenital diseases that may affect the development of the nervous system (such as Down's Syndrome);
  8. Allergy to dexmedetomidine;
  9. Other conditions that are considered unsuitable for study participation by the attending pediatricians or investigators.

Sites / Locations

  • Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Dexmedetomidine group

Control group

Arm Description

A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.

Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.

Outcomes

Primary Outcome Measures

Intelligence Quotient
Tested with Chinese Binet Intelligence Scale

Secondary Outcome Measures

Time to anesthesia emergence
Time to extubation
Depth of sedation at the time of extubation
Assessed with Ramsay sedation scale
Emergence agitation
Agitation will be assessed with anesthesia emergence agitation score.

Full Information

First Posted
June 8, 2016
Last Updated
September 28, 2016
Sponsor
Peking University First Hospital
Collaborators
Beijing Tiantan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02810899
Brief Title
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
Official Title
The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
September 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University First Hospital
Collaborators
Beijing Tiantan Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this randomized, double-blind and placebo-controlled pilot study is to investigate whether dexmedetomidine when used as an adjuvant to general anesthesia can decrease the harmful effects of anesthesia and surgery on intelligence development in pediatric patients undergoing craniotomy.
Detailed Description
General anesthetics and sedatives are administered to millions of children each year to facilitate life-saving surgery and other essential surgical or medical procedures. In the past two decades, mounting evidence from animal and clinical studies have raised concerns that general anesthetics may produce harmful effects in the developing brain and lead to adverse neurodevelopmental outcomes. Factors that may influence the degree of injury include age at the time of drug exposure/surgery and cumulative anesthetic dose. The Intelligence Quotients of pediatric patients with intracranial tumors are lower when compared with healthy children of same age. The investigators suppose that these patients are more sensitive to the neurotoxic effects of general anesthetics. Dexmedetomidine is an alpha 2-adrenoceptor agonist that provides sedation, anxiolysis, and analgesia, and has been shown to be safe to the brain in animal studies. In clinical studies, the use of dexmedetomidine decreases the consumption of anesthetics and opioids during general anesthesia and suppresses stress response induced by surgery. The investigators hypothesize that dexmedetomidine, when used as an adjuvant to general anesthesia, can reduce the neurotoxic effects of general anesthetics by decreasing anesthetic consumption and inhibiting stress response. The purpose of this randomized, double-blind and placebo-controlled pilot study is to investigate whether dexmedetomidine, when used as an adjuvant to general anesthesia, can decrease the harmful effects of anesthesia and surgery on intelligence development of pediatric patients undergoing craniotomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Neoplasms
Keywords
child, craniotomy, intelligence tests, dexmedetomidine, Disruption, Dehiscence, Mild Cognitive Disorder

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine group
Arm Type
Experimental
Arm Description
A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
Intervention Type
Drug
Intervention Name(s)
dexmedetomidine
Other Intervention Name(s)
dexmedetomidine hydrochloride
Intervention Description
A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
Intervention Type
Drug
Intervention Name(s)
normal saline
Other Intervention Name(s)
0.9% sodium chloride
Intervention Description
Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
Primary Outcome Measure Information:
Title
Intelligence Quotient
Description
Tested with Chinese Binet Intelligence Scale
Time Frame
At 3 months after surgery
Secondary Outcome Measure Information:
Title
Time to anesthesia emergence
Time Frame
From end of surgery until reappearance of response to oral orders, assessed up to 24 hours
Title
Time to extubation
Time Frame
From end of surgery until extubation, assessed up to 24 hours
Title
Depth of sedation at the time of extubation
Description
Assessed with Ramsay sedation scale
Time Frame
Immediately after extubation
Title
Emergence agitation
Description
Agitation will be assessed with anesthesia emergence agitation score.
Time Frame
From end of surgery until extubation, assessed up to 24 hours
Other Pre-specified Outcome Measures:
Title
Length of stay in hospital after surgery
Time Frame
From end of surgery to 30 days after surgery
Title
Incidence of postoperative complications
Time Frame
From end of surgery to 30 days after surgery
Title
All-cause 30-day mortality
Time Frame
At the time of 30 days after surgery
Title
All-cause 90-day mortality
Time Frame
At the time of 90 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of 2 years or older, but no more than 12 years; Plan to undergo selective craniotomy under general anesthesia for intracranial tumor resection; Written informed consent signed by legal guardians. Exclusion Criteria: Refused to participate by the legal guardians; Body weight lower than the 3rd percentile or higher than 97th percentile of the normal body weight reference; American Society of Anesthesiologists physical classification of IV or higher; Unable to complete preoperative intelligence assessment because of coma, dysnoesia, or language barrier; Diagnosed pulmonary disease (including acute respiratory tract infection) or cardiovascular disease (including congenital heart disease, hypertension, hypotension, bradycardia, atrioventricular block, or cardiac insufficiency); Abnormal liver or renal function (liver enzyme or creatinine higher than 1.5 times of the upper normal limit; Other congenital diseases that may affect the development of the nervous system (such as Down's Syndrome); Allergy to dexmedetomidine; Other conditions that are considered unsuitable for study participation by the attending pediatricians or investigators.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dong-Xin Wang, MD, PhD
Organizational Affiliation
Peking University First Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100034
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
25714157
Citation
Rappaport BA, Suresh S, Hertz S, Evers AS, Orser BA. Anesthetic neurotoxicity--clinical implications of animal models. N Engl J Med. 2015 Feb 26;372(9):796-7. doi: 10.1056/NEJMp1414786.
Results Reference
background
PubMed Identifier
18499599
Citation
Cattano D, Young C, Straiko MM, Olney JW. Subanesthetic doses of propofol induce neuroapoptosis in the infant mouse brain. Anesth Analg. 2008 Jun;106(6):1712-4. doi: 10.1213/ane.0b013e318172ba0a.
Results Reference
background
PubMed Identifier
9872743
Citation
Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999 Jan 1;283(5398):70-4. doi: 10.1126/science.283.5398.70.
Results Reference
background
PubMed Identifier
11303910
Citation
Olney JW, Ishimaru MJ, Bittigau P, Ikonomidou C. Ethanol-induced apoptotic neurodegeneration in the developing brain. Apoptosis. 2000 Dec;5(6):515-21. doi: 10.1023/a:1009685428847.
Results Reference
background
PubMed Identifier
23722106
Citation
Jevtovic-Todorovic V, Absalom AR, Blomgren K, Brambrink A, Crosby G, Culley DJ, Fiskum G, Giffard RG, Herold KF, Loepke AW, Ma D, Orser BA, Planel E, Slikker W Jr, Soriano SG, Stratmann G, Vutskits L, Xie Z, Hemmings HC Jr. Anaesthetic neurotoxicity and neuroplasticity: an expert group report and statement based on the BJA Salzburg Seminar. Br J Anaesth. 2013 Aug;111(2):143-51. doi: 10.1093/bja/aet177. Epub 2013 May 30.
Results Reference
background
PubMed Identifier
15386759
Citation
Poggi G, Liscio M, Galbiati S, Adduci A, Massimino M, Gandola L, Spreafico F, Clerici CA, Fossati-Bellani F, Sommovigo M, Castelli E. Brain tumors in children and adolescents: cognitive and psychological disorders at different ages. Psychooncology. 2005 May;14(5):386-95. doi: 10.1002/pon.855.
Results Reference
background
PubMed Identifier
14527495
Citation
Hernandez MT, Sauerwein HC, Jambaque I, de Guise E, Lussier F, Lortie A, Dulac O, Lassonde M. Attention, memory, and behavioral adjustment in children with frontal lobe epilepsy. Epilepsy Behav. 2003 Oct;4(5):522-36. doi: 10.1016/j.yebeh.2003.07.014.
Results Reference
background
PubMed Identifier
26016707
Citation
Wang XW, Cao JB, Lv BS, Mi WD, Wang ZQ, Zhang C, Wang HL, Xu Z. Effect of perioperative dexmedetomidine on the endocrine modulators of stress response: a meta-analysis. Clin Exp Pharmacol Physiol. 2015 Aug;42(8):828-36. doi: 10.1111/1440-1681.12431.
Results Reference
background
PubMed Identifier
26991622
Citation
Li Y, Wang B, Zhang LL, He SF, Hu XW, Wong GT, Zhang Y. Dexmedetomidine Combined with General Anesthesia Provides Similar Intraoperative Stress Response Reduction When Compared with a Combined General and Epidural Anesthetic Technique. Anesth Analg. 2016 Apr;122(4):1202-10. doi: 10.1213/ANE.0000000000001165.
Results Reference
background
PubMed Identifier
26446479
Citation
Kim DJ, Kim SH, So KY, Jung KT. Effects of dexmedetomidine on smooth emergence from anaesthesia in elderly patients undergoing orthopaedic surgery. BMC Anesthesiol. 2015 Oct 7;15:139. doi: 10.1186/s12871-015-0127-4.
Results Reference
background
PubMed Identifier
26005187
Citation
Le Bot A, Michelet D, Hilly J, Maesani M, Dilly MP, Brasher C, Mantz J, Dahmani S. Efficacy of intraoperative dexmedetomidine compared with placebo for surgery in adults: a meta-analysis of published studies. Minerva Anestesiol. 2015 Oct;81(10):1105-17. Epub 2015 May 25.
Results Reference
background

Learn more about this trial

Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy

We'll reach out to this number within 24 hrs